Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Frank Stokes is Chief Financial Officer at Castle Biosciences. OQRO lists 4 transactions filed with the SEC under this name, the latest on Jun 22, 2026, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
4
Companies involved
2
As of the latest filing on , Frank Stokes reported holding 35,319 shares of Castle Biosciences (CSTL), worth about $1.19M at the last close of $34 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Castle Biosciences CSTL | 35,319 | 35K direct | $34 | $1.19M | Feb 20, 2025 |
Is this Frank Stokes’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
ExagenXGN
Jun 9, 202638Kdisclosed Jun 22
DetailsOfficial recordCastle BiosciencesCSTL
3 disclosures · Nov 2024 – Feb 2025 · 3 sold
Feb 20, 2025Sold~$215Kdisclosed Feb 24
DetailsOfficial recordNov 15, 2024Sold~$183Kdisclosed Nov 19
DetailsOfficial recordNov 15, 2024Sold~$24Kdisclosed Nov 19
DetailsOfficial recordFrank Stokes has no open-market purchase on record since 2020. Sales in 4 of the 7 years since 2020.
Frank Stokes reported 0 open-market purchases and 28 sales since 2020; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $215K1×1 trade |
| 2024 | — | $464K4×4 trades |
| 2021 | — | $2.27M9×9 trades |
| 2020 | — | $4.03M14×14 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Feb 20, 2025, Frank Stokes reported holding 35,319 shares of Castle Biosciences (CSTL). At the last close of $34 on Nov 13, 2026, that is about $1.19M. This is the stake disclosed in filings, not a net worth.
Frank Stokes has no open-market purchase on record since 2020. Sales in 4 of the 7 years since 2020.
In SEC filings since 2020: no open-market purchase is on record; the latest open-market sale is from 2025.
Castle Biosciences (CSTL), from 2020 to 2025: 0 purchases and 28 sales.
Frank Stokes reported 0 open-market purchases and 28 sales here, 2020 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
